Skip to the page
Get started free

Data / Drug companies / Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited: 37 products in the FDA NDC directory, labeler code 11532

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Takeda Pharmaceutical Company Limited (labeler code 11532) lists 37 products in the FDA National Drug Code Directory. By type: 36 drugs for further processing, 1 bulk ingredients. Its main marketing category is drugs for further processing. The newest product started marketing on May 20, 2014.

The request: Watch Takeda Pharmaceutical Company Limited (FDA labeler code 11532): each new product listing and each discontinued product. $10 of work on sign-up, no card.

Watch Takeda Pharmaceutical Company LimitedAdd company details

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
11532
Products in commercial distribution
37
Packages
37
Finished drugs by generic name
0
Prescription products
0
Over the counter products
0
Started marketing in the last 12 months
0
Earliest marketing start
January 26, 1989
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Drugs for further processing3697.3%
Bulk ingredients12.7%

Products by type

TypeProductsShare
Drugs for further processing3697.3%
Bulk ingredients12.7%

Dosage forms

Dosage formProductsShare
Tablet1335.1%
Injection, powder, lyophilized, for suspension1129.7%
Tablet, film coated1129.7%
Injection, powder, lyophilized, for solution12.7%
Powder12.7%

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Vedolizumab11532-3002Injection, powder, lyophilized, for solutionDrugs for further processingMay 20, 2014
Alogliptin and metformin hydrochloride11532-1255Tablet, film coatedDrugs for further processingFebruary 5, 2013
Alogliptin and metformin hydrochloride11532-1251Tablet, film coatedDrugs for further processingFebruary 5, 2013
Alogliptin/pioglitazone11532-7106Tablet, film coatedDrugs for further processingFebruary 7, 2012
Alogliptin/pioglitazone11532-7105Tablet, film coatedDrugs for further processingFebruary 7, 2012
Alogliptin/pioglitazone11532-7104Tablet, film coatedDrugs for further processingFebruary 7, 2012
Alogliptin/pioglitazone11532-7103Tablet, film coatedDrugs for further processingFebruary 7, 2012
Alogliptin/pioglitazone11532-7102Tablet, film coatedDrugs for further processingFebruary 7, 2012
Alogliptin/pioglitazone11532-7101Tablet, film coatedDrugs for further processingFebruary 7, 2012
Alogliptin11532-7003Tablet, film coatedDrugs for further processingFebruary 7, 2012
Alogliptin11532-7002Tablet, film coatedDrugs for further processingFebruary 7, 2012
Alogliptin11532-7001Tablet, film coatedDrugs for further processingFebruary 7, 2012
Azilsartan medoxomil and chlorthalidone11532-6004TabletDrugs for further processingDecember 23, 2011
Azilsartan medoxomil and chlorthalidone11532-6002TabletDrugs for further processingDecember 23, 2011
Azilsartan medoxomil and chlorthalidone11532-6003TabletDrugs for further processingOctober 11, 2011
Azilsartan medoxomil and chlorthalidone11532-6001TabletDrugs for further processingOctober 11, 2011
Leuprolide acetate11532-1457Injection, powder, lyophilized, for suspensionDrugs for further processingAugust 15, 2011
Leuprolide acetate11532-1456Injection, powder, lyophilized, for suspensionDrugs for further processingAugust 15, 2011
Leuprolide acetate11532-1455Injection, powder, lyophilized, for suspensionDrugs for further processingJune 17, 2011
Pioglitazone hydrochloride11532-5001PowderBulk ingredientsMay 31, 2011
Azilsartan kamedoxomil11532-2003TabletDrugs for further processingFebruary 25, 2011
Azilsartan kamedoxomil11532-2002TabletDrugs for further processingFebruary 25, 2011
Leuprolide acetate11532-3680Injection, powder, lyophilized, for suspensionDrugs for further processingAugust 23, 2010
Pioglitazone hydrochloride and glimepiride11532-3043TabletDrugs for further processingJuly 28, 2006
Pioglitazone hydrochloride and glimepiride11532-3023TabletDrugs for further processingJuly 28, 2006

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.